Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
303 questions in 64 reviews · Hepato-Biliary
current versionsNo studies 303 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone All‐cause mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs conventional surgery Health‐related quality of life · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs conventional surgery Failure to clear liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs conventional surgery Recurrence of liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs radiofrequency ablation Health‐related quality of life · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation vs radiofrequency ablation Disease‐free survival · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Time to mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Health‐related quality of life · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Disease‐free survival · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Failure to clear liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Recurrence of liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane | no estimate extracted | NR | No studies |
Transjugular intrahepatic portosystemic shunts vs conventional treatment Health‐related quality of life · adults with hepatorenal syndrome Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · participants with gallstone disease (cholesterol, pigment, or mixed) Modified dietary fat intake for treatment of gallstone disease in people of any age (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious adverse events at longest · participants with gallstone disease (cholesterol, pigment, or mixed) Modified dietary fat intake for treatment of gallstone disease in people of any age (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · participants with gallstone disease (cholesterol, pigment, or mixed) Modified dietary fat intake for treatment of gallstone disease in people of any age (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs shallow NMB All‐cause mortality ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs shallow NMB Health‐related quality of life ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs no NMB All‐cause mortality start of surgery ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Deep neuromuscular blockade (NMB) vs no NMB Health‐related quality of life ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures Deep neuromuscular blockade in adults undergoing an abdominal laparoscopic procedure (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with disease progression · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Overall survival · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Adverse events considered non‐serious (number of events) · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Overall survival · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with disease progression · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Endoscopic sphincterotomy vs endoscopic papillary balloon dilation All‐cause mortality (or overall survival) ‐ not reported · adults with biliary sphincter of Oddi dysfunction Endoscopic sphincterotomy for adults with biliary sphincter of Oddi dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Endoscopic sphincterotomy vs endoscopic papillary balloon dilation Proportion of participants with ≥ 1 non‐serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction Endoscopic sphincterotomy for adults with biliary sphincter of Oddi dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Biliary endoscopic sphincterotomy vs dual endoscopic sphincterotomy Proportion of participants with ≥ 1 serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction Endoscopic sphincterotomy for adults with biliary sphincter of Oddi dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Biliary endoscopic sphincterotomy vs dual endoscopic sphincterotomy Health‐related quality of life ‐ not reported · adults with biliary sphincter of Oddi dysfunction Endoscopic sphincterotomy for adults with biliary sphincter of Oddi dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Biliary endoscopic sphincterotomy vs dual endoscopic sphincterotomy All‐cause mortality (or overall survival) ‐ not reported · adults with biliary sphincter of Oddi dysfunction Endoscopic sphincterotomy for adults with biliary sphincter of Oddi dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Biliary endoscopic sphincterotomy vs dual endoscopic sphincterotomy Proportion of participants with ≥ 1 non‐serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction Endoscopic sphincterotomy for adults with biliary sphincter of Oddi dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Endoscopic sphincterotomy vs sham treatment All‐cause mortality (or overall survival) ‐ not reported · adults with biliary sphincter of Oddi dysfunction Endoscopic sphincterotomy for adults with biliary sphincter of Oddi dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Endoscopic sphincterotomy vs sham treatment Proportion of participants with ≥ 1 non‐serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction Endoscopic sphincterotomy for adults with biliary sphincter of Oddi dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Endoscopic sphincterotomy vs endoscopic papillary balloon dilation Proportion of participants without successful treatment ‐ not reported · adults with biliary sphincter of Oddi dysfunction Endoscopic sphincterotomy for adults with biliary sphincter of Oddi dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Endoscopic sphincterotomy vs endoscopic papillary balloon dilation Health‐related quality of life ‐ not reported · adults with biliary sphincter of Oddi dysfunction Endoscopic sphincterotomy for adults with biliary sphincter of Oddi dysfunction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Antibiotics vs other antibiotics Serious adverse events ‐ not reported · farmworkers Antibiotic prophylaxis for leptospirosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Antibiotics vs other antibiotics Quality of life ‐ not reported · farmworkers Antibiotic prophylaxis for leptospirosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Antibiotics vs placebo or no intervention Serious adverse events ‐ not reported · farmworkers, soldiers, and people in endemic areas Antibiotic prophylaxis for leptospirosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Antibiotics vs placebo or no intervention Quality of life ‐ not reported · farmworkers, soldiers, and people in endemic areas Antibiotic prophylaxis for leptospirosis (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Antibiotics vs other antibiotics All‐cause mortality ‐ not reported · farmworkers Antibiotic prophylaxis for leptospirosis (2024) · Cochrane | no estimate extracted | NR | No studies |